Does IMATINIB Cause Neoplasm recurrence? 98 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 98 reports of Neoplasm recurrence have been filed in association with IMATINIB (Imatinib). This represents 0.2% of all adverse event reports for IMATINIB.
98
Reports of Neoplasm recurrence with IMATINIB
0.2%
of all IMATINIB reports
15
Deaths
15
Hospitalizations
How Dangerous Is Neoplasm recurrence From IMATINIB?
Of the 98 reports, 15 (15.3%) resulted in death, 15 (15.3%) required hospitalization.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 98 reports have been filed with the FAERS database.
What Other Side Effects Does IMATINIB Cause?
Death (9,708)
Drug ineffective (2,628)
Nausea (2,379)
Diarrhoea (2,203)
Fatigue (1,810)
Malignant neoplasm progression (1,716)
Vomiting (1,599)
Malaise (1,361)
Drug intolerance (1,354)
Drug resistance (1,293)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which IMATINIB Alternatives Have Lower Neoplasm recurrence Risk?
IMATINIB vs IMBRUVICA
IMATINIB vs IMDEVIMAB
IMATINIB vs IMEGLIMIN
IMATINIB vs IMETELSTAT
IMATINIB vs IMIDAPRIL